Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The real-world outcomes of multiple myeloma patients treated with daratumumab.
Szabo AG, Klausen TW, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Gjerdrum LMR, Bønløkke ST, Nielsen K, Kjeldsen E, Iversen KF, Teodorescu EM, Dokhi M, Kurt E, Strandholdt C, Andersen MK, Vangsted AJ. Szabo AG, et al. Among authors: bonlokke st. PLoS One. 2021 Oct 13;16(10):e0258487. doi: 10.1371/journal.pone.0258487. eCollection 2021. PLoS One. 2021. PMID: 34644367 Free PMC article.
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
Højholt KL, Gregersen H, Szabo AG, Klausen TW, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Rahbek Gjerdrum LM, Bønløkke ST, Nielsen K, Kjeldsen E, Iversen KF, Teodorescu EM, Kurt E, Strandholdt C, Andersen MK, Vangsted AJ. Højholt KL, et al. Among authors: bonlokke st. Hematol Oncol. 2021 Oct;39(4):521-528. doi: 10.1002/hon.2906. Epub 2021 Aug 2. Hematol Oncol. 2021. PMID: 34342035
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.
Szabo AG, Thorsen J, Iversen KF, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Gjerdrum LMR, Bønløkke ST, Nielsen K, Kjeldsen E, Teodorescu EM, Dokhi M, Kurt E, Strandholdt CN, Andersen MK, Vangsted AJ. Szabo AG, et al. Among authors: bonlokke st. Am J Hematol. 2022 Mar 1;97(3):E117-E120. doi: 10.1002/ajh.26449. Epub 2021 Dec 29. Am J Hematol. 2022. PMID: 34967035 Free article. No abstract available.
Altered Fibrinolysis in Hematological Malignances.
Bønløkke ST, Ommen HB, Hvas AM. Bønløkke ST, et al. Semin Thromb Hemost. 2021 Jul;47(5):569-580. doi: 10.1055/s-0041-1725099. Epub 2021 May 31. Semin Thromb Hemost. 2021. PMID: 34058766
Platelet characteristics in patients with essential thrombocytosis.
Pedersen OH, Larsen ML, Grove EL, van Kooten Niekerk PB, Bønløkke S, Nissen PH, Kristensen SD, Hvas AM. Pedersen OH, et al. Cytometry B Clin Cytom. 2018 Nov;94(6):918-927. doi: 10.1002/cyto.b.21642. Epub 2018 Sep 3. Cytometry B Clin Cytom. 2018. PMID: 29790256 Free article.
11 results